Synthesis, Antimycobacterial Activity and In Vitro Cytotoxicity of 5-Chloro-N-phenylpyrazine-2-carboxamides
暂无分享,去创建一个
O. Soukup | M. Doležal | J. Zítko | J. Kuneš | J. Mandíková | Barbora Servusová | V. Kubíček | P. Paterová | R. Kučera | Veronika Hrabcova
[1] M. Doležal,et al. Synthesis and antimycobacterial evaluation of N-substituted 5-chloropyrazine-2-carboxamides. , 2013, Bioorganic & medicinal chemistry letters.
[2] M. Lourenço,et al. Synthesis and Antitubercular Evaluation of N-Arylpyrazine and N,N′-Alkyl-diylpyrazine-2-carboxamide Derivatives. , 2013 .
[3] M. Doležal,et al. Synthesis and antimycobacterial evaluation of pyrazinamide derivatives with benzylamino substitution. , 2013, Bioorganic & medicinal chemistry letters.
[4] W. Jacobs,et al. Analogs of the Antituberculous Agent Pyrazinamide Are Competitive Inhibitors of NADPH Binding to M. tuberculosis Fatty Acid Synthase I , 2012, Chemistry & biodiversity.
[5] W. Jacobs,et al. Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis , 2012, The Indian journal of medical research.
[6] M. Doležal,et al. Substituted N-Benzylpyrazine-2-carboxamides: Synthesis and Biological Evaluation † , 2012, Molecules.
[7] J. Jampílek,et al. Pyrazinecarboxylic Acid Derivatives with Antimycobacterial Activity , 2012 .
[8] P. Cardona. Understanding Tuberculosis - New Approaches to Fighting Against Drug Resistance , 2012 .
[9] P. Wangikar,et al. Protective effect of curcumin, silymarin and N-acetylcysteine on antitubercular drug-induced hepatotoxicity assessed in an in vitro model , 2012, Human & experimental toxicology.
[10] M. Doležal,et al. Antimycobacterial evaluation of pyrazinoic acid reversible derivatives. , 2011, Current pharmaceutical design.
[11] P. Wangikar,et al. Studies on toxicity of antitubercular drugs namely isoniazid, rifampicin, and pyrazinamide in an in vitro model of HepG2 cell line , 2011, Medicinal Chemistry Research.
[12] W. Peters,et al. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity. , 2008, International journal of antimicrobial agents.
[13] J. N. Low,et al. Patterns of hydrogen bonding in mono- and di-substituted N-arylpyrazinecarboxamides. , 2008, Acta crystallographica. Section B, Structural science.
[14] A. J. van der Ven,et al. Antituberculosis drug‐induced hepatotoxicity: Concise up‐to‐date review , 2008, Journal of gastroenterology and hepatology.
[15] W. Jacobs,et al. Inhibition of Isolated Mycobacterium tuberculosis Fatty Acid Synthase I by Pyrazinamide Analogs , 2007, Antimicrobial Agents and Chemotherapy.
[16] D. Mitchison,et al. The curious characteristics of pyrazinamide: a review. , 2003, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[17] Clifton E. Barry,et al. Effects of Pyrazinamide on Fatty Acid Synthesis by Whole Mycobacterial Cells and Purified Fatty Acid Synthase I , 2002, Journal of bacteriology.
[18] William R. Jacobs,et al. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis , 2000, Nature Medicine.
[19] M. Cynamon,et al. In Vitro Antimycobacterial Activity of 5-Chloropyrazinamide , 1998, Antimicrobial Agents and Chemotherapy.
[20] R. Jones,et al. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination , 1987, Journal of clinical microbiology.
[21] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.